Montreal Cognitive Assessment and Modified Mini Mental State Examination in African Americans

Kaycee M. Sink,1 Suzanne Craft,1 S. Carrie Smith,2 Joseph A. Maldjian,3 Donald W. Bowden,2 Jianzhao Xu,2 Barry I. Freedman,4 and Jasmin Divers5

1Department of Internal Medicine (Geriatrics), Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
2Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
3Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
4Department of Internal Medicine (Nephrology), Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
5Department of Biostatistics, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

Correspondence should be addressed to Kaycee M. Sink; kmsink@wakehealth.edu

Received 9 August 2015; Revised 9 October 2015; Accepted 15 October 2015

Background. Sparse data limit the interpretation of Montreal Cognitive Assessment (MoCA) scores, particularly in minority populations. Additionally, there are no published data on how MoCA scores compare to the widely used Modified Mini Mental State Examination (3MSE). We provide performance data on the MoCA in a large cohort of African Americans and compare 3MSE and MoCA scores, providing a “crosswalk” for interpreting scores.

Methods. Five hundred and thirty African Americans with type 2 diabetes were enrolled in African American-Diabetes Heart Study-MIND, a cross-sectional study of cognition and structural and functional brain imaging. After excluding participants with possible cognitive impairment (n = 115), mean (SD) MoCA and 3MSE scores are presented stratified by age and education.

Results. Participant mean age was 58.2 years (range: 35-83); 61% were female; and 64.9% had >12 years of education. Mean (SD) 3MSE and MoCA scores were 86.9 (8.2) and 19.8 (3.8), respectively. 93.5% of the cohort had a “positive” screen on the MoCA, scoring <26 (education-adjusted), compared with 47.5% on the 3MSE (cut-point <88). A 3MSE score of 88 corresponded to a MoCA score of 20 in this population.

Conclusion. The present data suggest the need for caution when applying proposed MoCA cutoffs to African Americans.

1. Introduction

With the aging population there is a concomitant diversification of the United States such that, by 2050, it is predicted that the proportion of ethnic minority older adults (≥65) will nearly double (from 19.7% in 2012 to 39.1% in 2050) [1]. Thus, it is critical that cognitive screening tools be useful, applicable, and interpretable in a wide variety of settings and populations.

The Montreal Cognitive Assessment (MoCA) is a freely available screening test of global cognitive function that has been translated into 53 languages (http://www.mocatest.org/) [2]. Though increasingly used, interpretation of MoCA scores in research settings and in diverse populations remains limited by sparse data and lack of comparative data with other tests. The largest source of normative data on the MoCA for US populations comes from the Dallas Heart Study, where 2653 participants were tested [3]. The Dallas Heart Study cohort is ethnically diverse; however, the published data does not provide race-/ethnicity-specific norms based on age or education. This limits the usefulness of the MoCA in minority patients and research participants.

There is also little information regarding how MoCA scores relate to other commonly used cognitive screening tests. Only a few studies have compared the MoCA to the Mini Mental State Examination (MMSE) [4–6], and none, that we are aware of, compared it to the widely used Modified Mini Mental State Examination (3MSE) [7].

The objective of this report is to provide performance data on the MoCA in a large cohort of African Americans and to compare 3MSE and MoCA scores to provide a “crosswalk” for interpreting scores in middle-aged and older
African American-Diabetes Heart Study MIND (AA-DHS MIND) study enrollees. These data should help clinicians and researchers interpret MoCA scores in African Americans. They will also be useful for comparing MoCA scores to expected 3MSE scores for clinical assessment and/or inclusion/exclusion criteria in research studies.

2. Methods

2.1. Participants. The AA-DHS MIND enrolled 530 African Americans with type 2 diabetes (T2D) at the Wake Forest School of Medicine (WFSM). T2D was diagnosed in those with clinical disease onset after 30 years of age in the absence of diabetic ketoacidosis and in the setting of (a) active medical treatment (insulin and/or oral hypoglycemic agents), (b) fasting blood sugar > 126 mg/dL (7 mmol/L) or nonfasting blood sugar > 200 mg/dL (11.1 mmol/L), or (c) hemoglobin A1c (HbA1c) > 6.5%.

2.2. Measures/Assessments. Demographic data, medical history, current medications, and vital signs were recorded. Participants self-identified as African American. Participants had a fasting blood draw on which a variety of assays were performed including measures of serum creatinine, blood urea nitrogen, lipids, thyroid stimulating hormone, and vitamin B12 (LabCorp, Burlington, NC). After a morning snack, cognitive testing was performed. This study was approved by the WFSM Institutional Review Board and all participants provided written informed consent.

Cognition was assessed with a 45-minute battery of standard neuropsychological tests chosen to represent a broad variety of cognitive domains, with emphasis on executive function due to the known association between vascular cognitive impairment and executive dysfunction [8]. Global cognition was assessed with the 3MSE [9] and the MoCA [2]. The Rey Auditory Verbal Learning Test (RAVLT) [10] was used to assess learning and memory. Executive function was assessed with the WAIS-III Digit Symbol Coding (DSC) [11] (measuring speed of processing and working memory), the Stroop test [12] (measuring response inhibition), and verbal fluency for animals. Depression was assessed with the Center for Epidemiologic Studies Short Depression scale (CES-D10) [13,14]. Interviewees were trained, certified, and subsequently assessed for quality control in all cognitive tests by a single investigator (KMS).

2.3. Exclusions for Possible Cognitive Impairment. In an attempt to provide mean (SD) performance data as close to normative data as possible, we excluded participants from the analyses if they had conditions that could cause cognitive impairment or evidence of cognitive impairment on other tests in the neuropsychiatric battery. Participants were excluded from these analyses if they had evidence of hypothyroidism (TSH > 5.0 μIU/L; n = 24 excluded), vitamin B12 deficiency (B12 < 147.6 pmol/L; < 200 pg/mL; n = 12 excluded), or significant depression (defined as answering with “yes” to “I felt depressed” on 5–7 days of the last week; n = 32 excluded). Total CES-D 10 score was not used as a cutoff due to concerns that some of the items have been shown to be invalid in AA [15,16]. Using published normative data, we also excluded participants who performed worse than 1.5 SD below the mean for their age/education on verbal fluency for animals (n = 14 excluded) or the RAVLT long delay (n = 45 people). Other tests in our cognitive battery were not able to be used for exclusion purposes because reliable normative data in AA could not be found. In total, 115 participants (of 530) were excluded, leaving a sample size of 415 for these analyses.

2.4. Analyses. To determine whether the ordering of tests impacted scores, the first 200 study participants were randomized to receive the 3MSE or the MoCA as either the first or last test in the cognitive battery. Wilcoxon two-sample tests were used to compare the distribution of the observed 3MSE and MoCA scores by randomization order. Poisson-gamma models were also fitted to test for association between these scores and randomization order after adjusting for age, gender, and education level. There was no impact of test order on performance for either the 3MSE or MoCA (p value of 0.58 for 3MSE and 0.82 for MoCA; data not shown); therefore, 3MSE was administered first after the 200th participant and all subsequent analyses and presentation of results were done without regard to test order.

Demographic characteristics are presented using descriptive statistics, mean (SD) and %, for continuous and categorical variables, respectively. Means, medians, and SDs are presented for the MoCA and 3MSE by age and education. MoCA and 3MSE scores were compared using the Wilcoxon rank order test. Equipercentile matching was used to create a functional relationship between MoCA and 3MSE. Briefly, a 4th-degree polynomial log-linear equation was used to smooth the observed MoCA and 3MSE scores to reduce irregularities in the score distributions [17]. Equipercentile equating was then performed by determining the percentile rank of a given MoCA score and identifying the corresponding 3MS score that leads to the same ranking. Equipercentile analyses were performed with R-package Equate [18].

3. Results

Demographic and health characteristics of the participants are presented in Table 1. Participants had a mean age of 58.2 years (range: 35–83) and 61% were women. Nearly 65% had some college education; 19.8% had at least a four-year degree. The mean (SD) HbA1c was 8.0% (2.0) and the average duration of T2D was 13.0 (7.7) years. Although 83% of the sample had a diagnosis of hypertension, they were under relatively good control with mean (SD) systolic blood pressure of 131.4 (17.7) mm Hg.

MoCA. The mean (SD) MoCA score was 19.8 (3.8). Utilizing the <26 cutoff for impairment [2], 93.5% of our participants would be considered impaired after correction for education. Table 2 provides MoCA score means (SD) and medians by age and education. These scores are not corrected for education, given the fact that we stratified by education. Mean
### Table 1: Characteristics of 415 African Americans with type 2 diabetes mellitus.

| Variable                          | Mean (SD) or % | Range  |
|-----------------------------------|----------------|--------|
| **Demographics**                  |                |        |
| Age (years)                       | 58.2 (9.3)     | 35–83  |
| Female                            | 61.3           |        |
| Education (years)                 |                |        |
| <12                               | 10.8           |        |
| 12                                | 24.3           |        |
| 13–15                             | 45.1           |        |
| ≥16                               | 19.8           |        |
| **Health related characteristics**|                |        |
| Diabetes duration (years)         | 13.0 (7.7)     | 1.2–56.6|
| Body mass index (kg/m²)           | 35.9 (8.8)     | 17.9–75.7|
| Systolic blood pressure (mmHg)    | 131.4 (17.7)   | 78.5–194.0|
| Diastolic blood pressure (mmHg)   | 76.9 (11.2)    | 48.0–110.0|
| Smoking                           |                |        |
| Never                             | 46.7           |        |
| Past                              | 31.0           |        |
| Current                           | 22.3           |        |
| Hypertension (%)                  | 83.3           |        |
| Fasting glucose (mmol/L)          | 8.3 (3.6)      | 2.8–25.1|
| Hemoglobin A1c (%)                | 8.0 (2.0)      | 4.7–15.9|
| Serum creatinine (μmol/L)         | 88.4 (26.5)    | 40.7–388.1|
| Thyroid stimulating hormone (μIU/L)| 1.7 (1.0)      | 0.01–4.98|
| Vitamin B12 (pmol/L)              | 487.1 (272.9)  | 152.8–1476|
| **Cognitive function**            |                |        |
| MoCA (0–30)                       | 19.8 (3.8)     | 6–29   |
| 3MSE (0–100)                      | 86.9 (8.2)     | 46–100 |
| RAVLT delayed recall (0–15)       | 6.1 (2.9)      | 1–15   |
| DSC (0–133)                       | 51.1 (16.2)    | 2–96   |
| Verbal fluency for animals (0–undefined) | 16.1 (4.5) | 8–31 |
| Stroop interference (seconds)      | 37.1 (16.4)    | −20–134|

MoCA, Montreal Cognitive Assessment; 3MSE, Modified Mini Mental State Examination; RAVLT, Rey Auditory Verbal Learning Test; DSC, Digit Symbol Coding.

Scores decline with age (Spearman's rank correlation = −0.19, \( p < 0.001 \)). For example, amongst those with a high school education (12 years), participants who are less than 55 years old had a mean MoCA score of 20.5 compared to 19.8 for those who are 55 to 65 years old and 18.7 for those who are 65 years old and older. Similarly, scores were higher for those with greater education (Spearman's rank correlation = 0.39, \( p < 0.001 \)), with a 4–7-point spread between those with less than 12 years of education and those with a college degree or more (16+ years), depending on age (Table 2).

The mean (SD) 3MSE score for the cohort was 86.9 (8.2). Using a cutoff of <88 to define suspected impairment [19, 20], 47.5% of participants would be considered impaired. Table 3 provides 3MSE means (SD) and medians by age and education. Similar to the MoCA, 3MSE scores were affected by age (Spearman’s rank correlation = −0.20, \( p < 0.001 \)) and education (Spearman’s rank correlation = 0.41, \( p < 0.001 \)).

Figure 1 and Table 4 display how the MoCA and 3MSE scores relate using models based on equipercentile performance. For example, a score of 88 on the 3MSE is equivalent to a score of 20 on the MoCA.

### 4. Discussion

This report provides age- and education-stratified data for the MoCA and the 3MSE in a large sample of middle-aged and older-aged African Americans with T2D. As expected, age and education were significantly associated with performance on the MoCA, emphasizing the importance of basing conclusions on stratified data. With these data, clinicians can now compare the MoCA performance of African Americans in their office to mean scores of African Americans of a similar age and education level. This is important, because African Americans are known to perform worse on a variety of cognitive tests than European Americans, potentially due
to educational and socioeconomic factors, and thus race-specific normative data are critical for making accurate clinical assessments [21].

With that said, these results should not be considered strictly “normative” data as we did not clinically assess participants for cognitive impairment. When comparing the performance of AA-DHS MIND participants on the MoCA to African Americans in the Dallas Heart Study [3], AA-DHS MIND participants performed several points worse. The mean age of African Americans in the Dallas Heart Study was younger (49.9 years compared to 58.2 years in AA-DHS MIND), with similar mean levels of education, yet the mean (SD) MoCA score was 22 (4). Data specific to African Americans in the Dallas Heart Study were not presented by age/education. The youngest AA-DHS MIND group (age < 55 years) with 13–15 years of education had mean (SD) MoCA scores of 20.7 (3.4). Sixty-two percent of Dallas Heart Study participants fell below the education-corrected cut-point of 26, compared to 93.5% of AA-DHS MIND participants. Performance on the 3MSE was also lower in the AA-DHS MIND sample compared to 3MSE normative data published for a sample of 238 elderly African Americans residing in Tampa, FL [22]. The age strata presented were not the same, limiting direct comparisons between reports. However, mean 3MSE scores in AA-DHS MIND participants who are 55–65 years old were several points lower than those in the participants who are 60–71 years old in the Tampa-based Brown et al.’s study across all education groups but particularly for participants with high school or less education.

There are several reasons why AA-DHS MIND MoCA and 3MSE scores may have been lower than those in published norms. First, all participants have T2D and diabetes has been shown to adversely impact cognition [23]. Second, there may be regional variation in cognitive performance among African Americans, such that those residing in North Carolina may perform worse than those in other regions of the country due to differences in cognitive risk factors (North Carolina is in the stroke belt) [24] or quality of education, especially in the southern US where older participants may have been educated in segregated, rural schools [21, 25]. There are other methodological considerations to factor in when interpreting the current results, including the fact that this was a single center study and results may not generalize to all African Americans based on presence of T2D. However, African Americans have a lifetime risk for T2D that exceeds 50% [26]. These data should not be interpreted as strictly “normative” since no clinical evaluation to determine cognitive status (normal or impaired) was performed. Therefore, we did not provide ROC curves with suggested “cutoffs” for the MoCA as a screening test in African Americans. However, we did exclude participants with hypothyroidism, vitamin B12 deficiency, and depressed mood as all of these conditions could have impacted test scores negatively. In addition, we excluded participants with evidence of memory impairment and poor category fluency for animals in a further attempt to provide data on participants that could be considered free of significant cognitive impairment. In addition, these participants volunteered to be in a research study and study volunteers are typically healthier than the general population (healthy volunteer effect).

In spite of these methodological limitations, there are several noteworthy strengths. We have presented the first report of MoCA scores stratified by age and education in a large sample of African Americans. In addition, we present the first “crosswalk” that can be used to compare

---

**Table 2: Montreal Cognitive Assessment (MoCA) scores by age and education in 414 African Americans.**

| Age (years) | <12 years | 12 years | 13–15 years | 16+ years | All |
|-------------|-----------|----------|-------------|----------|-----|
| <55         | 15        | 18.8 (3.1) 19.0 | 19.3 (3.9) 19.5 | 20.7 (3.4) 20.0 | 23.4 (3.1) 24.0 | 159 | 20.5 (3.8) 20.0 |
| 55–65       | 15        | 18.0 (3.0) 18.0 | 18.4 (3.7) 18.5 | 19.8 (3.3) 20.0 | 22.3 (3.6) 23.0 | 163 | 19.8 (3.7) 20.0 |
| >65         | 15        | 14.4 (3.3) 15.0 | 17.7 (4.2) 19.0 | 19.2 (2.9) 19.5 | 21.6 (3.1) 21.0 | 92  | 18.7 (3.9) 19.0 |
| All         | 45        | 17.1 (3.6) 17.0 | 18.7 (3.8) 19.0 | 19.9 (3.3) 20.0 | 22.5 (3.4) 23.0 | 414 | 19.8 (3.8) 20.0 |

Note: MoCA scores are raw scores, with no extra point given for education ≤12 years. N = 414, not 415, because age was missing for one person. Range for age <55 is 35–54; range for >65 is 66–83 years. For participants with <12 years of education, 11 had 5–8 years and 34 had 9–11 years.

**Table 3: Modified Mini Mental State Examination (3MSE) scores by age and education in 414 African Americans.**

| Age (years) | <12 years | 12 years | 13–15 years | 16+ years | All |
|-------------|-----------|----------|-------------|----------|-----|
| <55         | 15        | 82.7 (6.7) 85.0 | 86.6 (7.2) 88.0 | 89.0 (6.0) 89.5 | 94.2 (4.6) 95.0 | 159 | 88.5 (7.0) 89.0 |
| 55–65       | 15        | 79.7 (10.8) 84.0 | 84.1 (6.8) 84.0 | 87.9 (7.5) 89.0 | 90.1 (6.9) 92.0 | 163 | 86.7 (8.1) 87.0 |
| >65         | 15        | 73.9 (11.0) 74.0 | 81.1 (8.2) 82.0 | 86.4 (6.6) 86.0 | 90.2 (8.0) 92.0 | 92  | 84.4 (9.4) 88.0 |
| All         | 45        | 78.8 (10.2) 79.0 | 84.9 (7.4) 86.0 | 82.9 (6.8) 88.0 | 91.5 (6.7) 94.0 | 414 | 86.9 (8.2) 88.0 |

Note: N = 414, not 415, because age was missing for one person. Range for age <55 is 35–54; range for >65 is 66–83 years. For participants with <12 years of education, 11 had 5–8 years and 34 had 9–11 years.
Table 4: Conversion table between observed MoCA and 3MSE scores in African Americans.

| MOCA | 3MSE |
|------|------|
| 1    | 0–37 |
| 2    | 38–40|
| 3    | 41–42|
| 4    | 43–44|
| 5    | 45–46|
| 6    | 47–49|
| 7    | 50–52|
| 8    | 53–54|
| 9    | 55–57|
| 10   | 58–60|
| 11   | 61–64|
| 12   | 65–67|
| 13   | 68–70|
| 14   | 71–73|
| 15   | 74–76|
| 16   | 77–79|
| 17   | 80–81|
| 18   | 82–83|
| 19   | 84–86|
| 20   | 87–88|
| 21   | 89–90|
| 22   | 91   |
| 23   | 92–93|
| 24   | 94–95|
| 25   | 96   |
| 26   | 97–98|
| 27   | 99   |
| 28   | 100  |

scores between the MoCA and 3MSE. This is important because many large epidemiologic studies (examples include the Cardiovascular Health Study, Health ABC Study, Cache County Study, Women's Health Initiative, and Canadian Study of Health and Aging) and clinical trials (Women's Health Initiative Memory Study and Lifestyle Interventions and Independence for Elders (LIFE) Study) have used the 3MSE. In order to compare results in those studies with the more contemporary MoCA test, development of a crosswalk is necessary. This allows researchers to identify a MoCA score that would be comparable to a given 3MSE score for inclusion into or exclusion from a study based on previous studies and allows clinicians to translate risk associated with a specific 3MSE score to a MoCA score that they obtained in clinic in African Americans.

In conclusion, the present data suggests the need for caution when applying proposed MoCA cutoffs to African Americans. Based on the suggested cutoff of <26, 93.5% of AA-DHS MIND participants would have been classified as impaired, which is clearly unlikely. Additional studies using large, diverse populations, where MoCA scores can be stratified by race, age, and education, are needed. We also recommend that MoCA/3MSE comparisons be replicated in other cohorts to determine if our “crosswalk” of scores is applicable to other race/ethnicity groups.

Disclosure

Partial data was presented at Alzheimer's Association International Conference 2013. The sponsors had no role in the design or conduct of the study, collection, management, analysis, or interpretation of the data or preparation, review, or approval of the paper.

Disclaimer

Dr. Divers had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interests

All authors declare that there is no conflict of interests related to this paper.

Authors’ Contribution

Kaycee M. Sink participated in study design, interpretation of data, and drafting of the paper. Suzanne Craft participated in interpretation of data and critical revision of the paper. Carrie Smith took part in data acquisition, critical revision of the paper, and administrative support. Donald W. Bowden took part in study design, interpretation of data, and critical revision of the paper. Jianzhao Xu participated in data acquisition, critical revision of the paper, and administrative support. Joseph A. Maldjian had a role in study design, interpretation of data, critical revision of the paper, and obtaining funding. Barry I. Freedman took part in study design, interpretation of data, critical revision of the paper, and obtaining funding. Jasmin Divers had a role in study design, statistical analysis, interpretation of data, critical revision of the paper, and obtaining funding.

Acknowledgments

This study was funded by NIH R01 NS075107 (Jasmin Divers, Joseph A. Maldjian, and Barry I. Freedman), R01 NS-058700 (Donald W. Bowden), and R01 DK-071891 (Barry I. Freedman).

References

[1] J. M. Ortman, V. A. Velkoff, and H. Hogan, *An Aging Nation: The Older Population in the United States*, US Census Bureau, Washington, DC, USA, 2014.

[2] Z. S. Nasreddine, N. A. Phillips, V. Bédirian et al., “The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment,” *Journal of the American Geriatrics Society*, vol. 53, no. 4, pp. 695–699, 2005.
[3] H. C. Rossetti, L. H. Lacritz, C. Munro Cullum, and M. F. Weiner, “Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample,” Neurology, vol. 77, no. 13, pp. 1272–1275, 2011.

[4] Y. Dong, W. Y. Lee, N. A. Basri et al., “The Montreal cognitive assessment is superior to the mini-mental state examination in detecting patients at higher risk of dementia,” International Psychogeriatrics, vol. 24, no. 11, pp. 1749–1755, 2012.

[5] D. R. Roalf, P. J. Moberg, S. X. Xie, D. A. Wolk, S. T. Moelter, and S. E. Arnold, “Comparative accuracies of two common screening instruments for classification of Alzheimer’s disease, mild cognitive impairment, and healthy aging,” Alzheimer’s and Dementia, vol. 9, no. 5, pp. 529–537, 2013.

[6] S. Freitas, M. R. Simões, L. Alves, and I. Santana, “Montreal cognitive assessment: validation study for mild cognitive impairment and alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 27, no. 1, pp. 37–43, 2013.

[7] M. F. Folstein, S. E. Folstein, and P. R. McHugh, “‘Mini-mental state’ a practical method for grading the cognitive state of patients for the clinician,” Journal of Psychiatric Research, vol. 12, no. 3, pp. 189–198, 1975.

[8] S. T. Pendlebury, A. Markwick, C. A. de Jager, G. Zamboni, G. K. Wilcock, and P. M. Rothwell, “Differences in cognitive profile between TIA, stroke and elderly memory research subjects: a comparison of the MMSE and MoCA,” Cerebrovascular Diseases, vol. 34, no. 1, pp. 48–54, 2012.

[9] E. L. Teng and H. C. Chui, “The Modified Mini-Mental State (3MS) examination,” Journal of Clinical Psychiatry, vol. 48, no. 8, pp. 314–318, 1987.

[10] M. Lezak, Neuropsychological Assessment, Oxford University Press, New York, NY, USA, 1983.

[11] D. Wechsler, WAIS-III Manual, Psychological Corporation, New York, NY, USA, 1997.

[12] P. J. Houx, J. Jolles, and E. W. Vreeling, “Stroop interference: aging effects assessed with the Stroop Color-Word Test,” Experimental Aging Research, vol. 19, no. 3, pp. 209–224, 1993.

[13] M. Irwin, K. H. Artin, and M. N. Oxman, “Screening for depression in the older adult: criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D),” Archives of Internal Medicine, vol. 159, no. 15, pp. 1701–1704, 1999.

[14] E. M. Andresen, J. A. Malmgren, W. B. Carter, and D. L. Patrick, “Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale),” American Journal of Preventive Medicine, vol. 10, no. 2, pp. 77–84, 1994.

[15] E. Torres, “Psychometric properties of the center for epidemiologic studies depression scale in African American and black caribbean us adults,” Issues in Mental Health Nursing, vol. 33, no. 10, pp. 687–696, 2012.

[16] C. M. Callahan and F. D. Wolinsky, “The effect of gender and race on the measurement properties of the CES-D in older adults,” Medical Care, vol. 32, no. 4, pp. 341–356, 1994.

[17] P. W. Holland and D. T. Thayer, “Univariate and bivariate loglinear models for discrete test score distributions,” Journal of Educational and Behavioral Statistics, vol. 25, no. 2, pp. 133–183, 2000.

[18] A. Albano, Equate: Observed-Score Linking and Equating. R Package Version 2.0-3, 2014.

[19] S. R. Rapp, M. A. Espeland, P. Hogan, B. N. Jones, and E. Dugan, “Baseline experience with modified mini mental state exam: the Women’s Health Initiative Memory Study (WHIMS),” Aging & Mental Health, vol. 7, no. 3, pp. 217–223, 2003.

[20] K. M. Sink, M. A. Espeland, J. Rushing et al., “The LIFE Cognition Study: design and baseline characteristics,” Clinical Interventions in Aging, vol. 9, pp. 1425–1436, 2014.

[21] J. J. Manly, D. M. Jacobs, M. Sano et al., “Cognitive test performance among nondemented elderly African Americans and whites,” Neurology, vol. 50, no. 5, pp. 1238–1245, 1998.

[22] L. M. Brown, J. A. Schinka, J. A. Mortimer, and A. B. Graves, “3MS normative data for elderly African Americans,” Journal of Clinical and Experimental Neuropsychology, vol. 25, no. 2, pp. 234–241, 2003.

[23] S. Sadanand, R. Balachandar, and S. Bharath, “Memory and executive functions in persons with type 2 diabetes: a meta-analysis,” Diabetes/Metabolism Research and Reviews, 2015.

[24] V. G. Wadley, F. W. Unverzagt, L. C. McGuire et al., “Incident cognitive impairment is elevated in the stroke belt: the REGARDS Study,” Annals of Neurology, vol. 70, no. 2, pp. 229–236, 2011.

[25] J. J. Manly, D. A. Byrd, P. Touradj, and Y. Stern, “Acculturation, reading level, and neuropsychological test performance among African American elders,” Applied Neuropsychology, vol. 11, no. 1, pp. 37–46, 2004.

[26] E. W. Gregg, X. Zhuo, Y. J. Cheng, A. L. Albright, K. M. V. Narayan, and T. J. Thompson, “Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study,” The Lancet Diabetes and Endocrinology, vol. 2, no. 11, pp. 867–874, 2014.